A prospective, observational study of fidaxomicin use for Clostridioides difficile infection in France.
Benoit GueryPierre BergerRemy GauzitMagali GourdonFrédéric Barbutnull nullnull Dafne Study GroupPascale BémerEmilie BessèdeFabrice CamouVincent CattoirCarine CouzigouDominique DescampsAurélien DinhCaroline LauransJean-Philippe LavigneCatherine LechicheVéronique Leflon-GuiboutAlban Le MonnierMarion LevastJoy Yoganaden MootienYohan N'GuyenLionel PirothThierry PrazuckOlivier RogeauxAnne-Laure RouxAnne VachéeVéronique Vernet GarnierFrédéric WalletPublished in: The Journal of international medical research (2021)
Fidaxomicin is an effective and well-tolerated CDI treatment in a real-world setting in France, which included patients at high risk of adverse outcomes.Trial registration: Description of the use of fidaxomicin in hospitalised patients with documented Clostridium difficile infection and the management of these patients (DAFNE), NCT02214771, www.ClinicalTrials.gov.